Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis
Lab / animal
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study investigated the effects of atorvastatin and resveratrol on experimental endometriosis, examining their impact on glucose and monocarboxylate transporters and neoangiogenesis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The current study was conducted to investigate the therapeutic effects of atorvastatin (ATV) and resveratrol (RVT) in sole and simultaneous forms of administration against the symbiosis between glucose transporters 1 and 3 (GLUT-1 and GLUT-3), monocarboxylate transporters 1 a and 4 (MCT-1 and MCT-4) and neovascularization in ectopic endometrial tissue (EET). For this purpose, the experimental endometriosis was induced in 24 virgin female Wistar rats, and then the rats were divided into non-treated endometriosis-induced (ENDO-sole), AVT-treated (5 mg kg-1), RVT-treated (40 mg kg-1) and AVT +RVT-treated groups (n = 6 rats in each group). Following 28 days from the experimental endometriosis induction, the EETs were collected and the EETs size, neovascularization ratio, and expression levels of GLUT-1, GLUT-3, MCT-1, and MCT-4 were analyzed by qRT-PCR and immunohistochemistry (IHC). The AVT and RVT sole and simultaneous-treated animals exhibited decreased EET sizes and neovascularization. Moreover, the mRNA levels of GLUT-1, GLUT-3, MCT-1, and MCT-4, as well as GLUT-1+, GLUT-3+, and MCT-4+ cells distribution per mm2 of tissue were decreased in AVT and RVT sole and simultaneous-treated groups. Our findings showed that the AVT and RVT, especially in the simultaneous form of administration, could decrease the neovascularization development in the EETs by suppressing the GLUTs (1 and 3) and MCTs (1 and 4) expressions. Therefore, it can be concluded that the simultaneous administration of AVT and RVT can inhibit the EET's establishment and development through suppressing glycolysis and neovascularization.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (57)
- Adult stem cells in the endometrium via openalex
- Angiogenic factors in endometriosis via openalex
- Atorvastatin causes regression of endometriotic implants in a rat model via openalex
- Comparing protective effect of grape seed extract versus atorvastatin on endometriosis in rat model: Evidence for immunohistochemical and biochemical alterations via openalex
- Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development via openalex
- Endometriosis, angiogenesis and tissue factor via openalex
- Endostatin inhibits the growth of endometriotic lesions but does not affect fertility via openalex
- High-dose atorvastatin causes regression of endometriotic implants: a rat model via openalex
- Hypoxia: The force of endometriosis via openalex
- Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis via openalex
- New therapeutic approaches for endometriosis besides hormonal therapy via openalex
- Pro-inflammatory cytokines for evaluation of inflammatory status in endometriosis via openalex
- Serum cytokine and growth factor levels in patients with endometriosis via openalex
- Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model via openalex
- Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression via openalex
- Therapeutic Approaches of Resveratrol on Endometriosis via Anti-Inflammatory and Anti-Angiogenic Pathways via openalex
- The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial via openalex
- W2117264102 via openalex
- W2126255509 via openalex
- W2136927815 via openalex
- W2143365556 via openalex
- W2155590575 via openalex
- W2160852038 via openalex
- W2165235603 via openalex
- W2169379435 via openalex
- W2194839497 via openalex
- W190490415 via openalex
- W2342466981 via openalex
- W2562182278 via openalex
- W2765762940 via openalex
- W2784250532 via openalex
- W2808538861 via openalex
- W2889273501 via openalex
- W2891824977 via openalex
- W2971135934 via openalex
- W6638196710 via openalex
- W6681412198 via openalex
- W6684182588 via openalex
- W6730342182 via openalex
- W6767251668 via openalex
- W2219450326 via openalex
- W1589173706 via openalex
- W1813533435 via openalex
- W1988699352 via openalex
- W1990253071 via openalex
- W1998976350 via openalex
- W2015916684 via openalex
- W2020062992 via openalex
- W2026849379 via openalex
- W2049458423 via openalex
- W2062573649 via openalex
- W2062747831 via openalex
- W2068045057 via openalex
- W2073274327 via openalex
- W2101386379 via openalex
- W2103015234 via openalex
- W2111158723 via openalex
Cited by (22)
- The Role of Dietary Supplements in the Treatment of Endometriosis: A Critical Review 2026
- Revisiting endometriosis management: Polyphenols as alternative therapeutic candidates 2026
- Resveratrol as a protective and ameliorative agent in endometriosis 2026
- Glycolytic Reprogramming in Endometriosis: Biological Basis and Emerging Targets for Disease-Modifying Therapy 2026
- BDNF facilitates ectopic endometrial stromal cell growth, invasion, migration and glycolysis in endometriosis via upregulating GLUT1 2026
- Glycolytic reprogramming in endometriosis: molecular mechanisms, immune modulation, and non-hormonal therapeutic opportunities 2026
- Aberrant mitochondria in endometriosis: From pathogenic mechanisms to therapeutic opportunities 2026
- Metabolic reprogramming in endometriosis: mechanisms and therapeutic prospects 2026
- Warburg-like Metabolic Reprogramming in Endometriosis: From Molecular Mechanisms to Therapeutic Approaches 2025
- Molecular links in endometriosis pathogenesis as targets for diagnosis and targeted therapy: a review 2025
- Study on the relationship between the non-HDL/HDL cholesterol ratio (NHHR) and endometriosis: a cross-sectional analysis utilizing the NHANES dataset 2025
- New opportunities for correction of hormonal disorders and oxidative stress in women with genital endometriosis 2024
- Molecular Mechanism of Resveratrol and Its Therapeutic Potential on Female Infertility 2024
- Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis 2023
- Review of the Potential Therapeutic Effects and Molecular Mechanisms of Resveratrol on Endometriosis 2023
- Effects of SU5416 on angiogenesis and the ERK-VEGF/MMP-9 pathway in rat endometriosis. 2023
- Role of AMPK/mTOR, mitochondria, and ROS in the pathogenesis of endometriosis 2022
- Impact of curcumin, quercetin, or resveratrol on the pathophysiology of endometriosis: A systematic review 2022
- O potencial efeito do resveratrol no tratamento da endometriose 2022
- The Phytochemical Profile and Biological Activity of Malva neglecta Wallr. in Surgically Induced Endometriosis Model in Rats 2022
- Advances in the medical treatment of adolescent endometriosis 2021
- Phytoestrogens for the Management of Endometriosis: Findings and Issues 2021
Source provenance
- europepmc
- last seen: 2026-10-12T06:17:10.165071+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:30:01.769541+00:00
License: CC0
· commercial use OK